Clinical trials recruiting for Non-Small Cell Lung Cancer Metastatic
16
Recruiting trials
29
US states with sites
30
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 3 |
| New Jersey | 3 |
| New York | 3 |
| California | 2 |
| Pennsylvania | 2 |
| Alabama | 1 |
| Alaska | 1 |
| Arkansas | 1 |
| Colorado | 1 |
| Delaware | 1 |
| Georgia | 1 |
| Illinois | 1 |
Top cities
Basking Ridge, New Jersey 2Commack, New York 2Harrison, New York 2Miami, Florida 2Middletown, New Jersey 2Montvale, New Jersey 2New York, New York 2Rockville Centre, New York 2Sacramento, California 2Abilene, Texas 1
Self-screener
Recruiting trials
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
- A Phase Ib Study of GC101 in NSCLC
- A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
- A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
- Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
- Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
- First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
- PALACE: Cemiplimab Trial According to ctDNA Levels
- Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
- Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Related conditions
Trials recruiting for Non-Small Cell Lung Cancer Metastatic often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Non-small cell lung cancer 507Non Small Cell Lung Carcinoma 10Non-small Cell Carcinoma 4Thoracic Neoplasms 8Stage IV Non-small Cell Lung Cancer 7Stage III Non-small Cell Lung Cancer 6Small cell lung cancer 87Respiratory Tract Neoplasms 4Prostate Cancer Metastatic 27
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Non-Small Cell Lung Cancer Metastatic trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.